Andrew Penkethman – Managing Director and CEO – Ardea Resources (ASX:ARL) is advancing its flagship 100%-owned Kalgoorlie Nickel Project (KNP). KNP is the largest Nickel–Cobalt resource in Australia and in the top 10 globally, making it of a scale that is incredibly rare and important in the World’s journey to Net Zero. KNP was awarded Major Project Status by the Australian Federal Government, recognising the national and strategic significance of the KNP to the Australian economy and the Eastern Goldfields of Western Australia.
Copyright 2024 – Finance News Network
23 Mar 2022 - James Power, the General Manager - Investor Relations and Marketing of the Rural Funds Group (ASX:RFF), presents on the company's HY22 results.
10 Oct 2023 - Harry Fisher - Project Manager - Benchmark’s prices and data empowers clients: from critical mineral contracts to EV battery supply chain investments and government policy.
21 Sep 2020 - Clayton Utz Partner Brendan Bateman discusses climate change risks, the legal duties of directors and how to factor such risks into financial valuations.
03 February 2021 - Nyrada Limited (ASX:NYR) CEO James Bonnar talks about the company's collaboration agreement with the Walter Reed Army Institute of Research and UNSW into the study of a first-ever pharmaceutical treatment for traumatic brain injury, a top health priority for the military.
26 Feb 2021 - Anteris Technologies Limited (ASX:AVR) CEO & Managing Director Wayne Paterson talks about the benefits of the company's Anteris DurAVR aortic replacement valve to work better and for longer, company strategy and goals for 2021.
12 Aug 2020 - Galan Lithium Limited (ASX:GLN) Managing Director, Juan Pablo Vargas de la Vega talks about the company's lithium brine projects located within the South American Lithium Triangle in Argentina strategy and near-term targets.
15 Jul 2020 - Recce Pharmaceuticals Limited (ASX:RCE) Executive Director James Graham provides an update on positive data against a range of persistent bacteria using the company's synthetic antibiotic RECCE 327, commencement of Phase I human clinical trial in 2H20 and key priorities.
